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Introduction:Atrial ﬁbrillation (AF) is themost common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The
ﬁrst choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International
Normalized Ratio leads to the administration of direct-acting oral anticoagulants. There is a trend toward inadequate AT in nonvalvular
AF (NVAF) patients. Aim: To evaluate the impact of the implementation of a decision support tool linked to the digital clinical history on
the adequacy of AT, the incidence of complications, and the mortality in patients with NVAF in primary care centers (PCCs) of the
Catalan Institute of Health (ICS).
Methods and analysis: Randomized clinical trial in 287 PCCs, formed by 2 groups (intervention and control). Population:
patients controlled in PCCs, diagnosed with NVAF 1 year before the implementation of the decision support tool and with VKA
treatment over a minimum of 1 year. A simple randomization method will be performed at a sector level. The decision support tool will
be available for 1 year. The time in therapeutic range (TTR) will be available in the digital clinical history only to professionals of the
intervention group. The information system for primary care research development database will be used for the data extraction.
Statistical analysis will be done at 3 time points: before the implementation of the tool, at 1 year, and at 2 years after the beginning of
the intervention. Multilevel (patient and professional levels) logistic regression models will be used to estimate the effect of the
intervention.
Ethics and dissemination: This study protocol was approved by the Ethical Committee of Clinical Investigation of the Institut
Universitari d’Investigació en Atenció Primària Jordi Gol (code P17/091). Articles will be published in scientiﬁc journals.
Trial registration: Clinical-Trials.gov: NCT03367325.
Abbreviations: AF = atrial ﬁbrillation, AT = anticoagulant therapy, CDS-NVAF = clinical decision support tool for improving the
adequacy of anticoagulant therapy in NVAF, DOAC = direct-acting oral anticoagulant, INR = international normalized ratio, NVAF =
nonvalvular AF, PCC = primary care center, TTR = time in therapeutic range, VKA = vitamin k antagonist.
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Atrial ﬁbrillation (AF) is the most frequent type of cardiac
arrhythmia, and patients with AF have a 4 to 5-fold greater risk of
ischemic stroke than the general population.[1,2] This arrhythmia
affects more than 6 million people in the European Union, with
an estimated prevalence of 1.5% to 2% in the general population,
increasing to up to 24.4% in individuals of more than 85 years of
age.[1,3–5]
According to the European Heart Rhythm Association, non-
valvular AF (NVAF) is produced in the absence of mechanical
prosthetic heart valves and the absenceofmoderate to severemitral
stenosis.[6] NVAF carries an increased risk of death, morbidity,
and hospitalization with the subsequent increase in healthcare
costs.[1,7–9] Although the physiopathology of NVAF is well-
known, thediagnosis andmanagement of these patients needs tobe
improved.[10] The main objective of the management of these
patients is to reduce the symptoms and prevent the severe
complications associated with this arrhthymia. The prevention of
thromboembolic complications is based on antithrombotic
treatment with either oral anticoagulants or antiplatelet drugs.[1,8]
Vitamin K antagonists (VKAs) were the only oral anti-
coagulants available for many years. However, the characteristics
of VKAs may make their use in patients with NVAF challenging
in clinical practice, leading to difﬁculties in the management of
these patients and the need to adapt the therapy.[11] Recently,
direct-acting oral anticoagulants (DOACs) were developed and
have shown to be safe and effective in the prevention of stroke
and systemic embolism in patients with NVAF, although some
limitations have also been reported.[12]
Since the introduction of DOACs in Spain their use has been on
the rise. Nevertheless, data from the Catalan Health Service on
the adequacy of DOAC prescriptions indicate that according to
the recommendations of the pharmacotherapy commission more
than 25% of the patients are not candidates for dabigatran
treatment and are receiving it, whereas patients who are
candidates to this treatment are not receiving the drug.[13] These
results indicate a clear problem of adequacy to the anticoagulant
treatment. We believe that this problem is probably because of
the absence of any single variable in the electronic clinical history
of the Catalan Institute of Health (ICS) that provides direct
knowledge regarding control of the international normalized
ratio (INR), thereby making it difﬁcult to know the real level of
control in the previous 6months, and consequently, the adequacy
of treatment and the possible changes needed.
The present project has been designed taking into account the
above situation. The aim of the project is to improve the
information available in the electronic clinical history by direct
calculation of the time in the therapeutic range (TTR) once the
value of the last INR of NVAF patients receiving VKA has been
entered. When the TRT is < 65% at 6 months, an alert will be
activated andwill inform the professional of the need to evaluate a
change in the treatment. The TTR (calculated using the Rosendaal
method[14]) is a widely applied measure for the evaluation of the
adequacy of anticoagulant therapy (AT) with VKAs. In several
guidelines on themanagement ofAF theTTR is used as a treatment
control criterion, although the use of these guidelines are not
generalized throughout the world.[15] According to the recom-
mendations of theministry of health, social services and equality of
Spain (based on the National Institute for Health and Care
Excellence guideline[16]) for the use of DOAC in NVAF patients, a
TTR <65% is a criterion of poor VKA control.[11]
Despite the increasingly more frequent use of computerized
medical reminders, few studies have assessed their impact on2health outcomes. A systematic review showed that
notiﬁcations inﬂuence speciﬁc aspects of the prescription process
and may be an effective method to reduce the prescription of
contraindicated medications, although their impact on health
outcomes was not demonstrated.[22] Within the primary care
setting it was found that computerized clinical notiﬁcations
signiﬁcantly improved the adequacy of treatment in patients with
poorly controlled asthma and consequently reduced the rate of
reexacerbations during follow-up. Moreover, medical profes-
sionals considered these reminders to be particularly useful for
the identiﬁcation of patients with bad control.[23]
The present project aims to evaluate the impact of the
implementation of a clinical decision support tool associated with
the electronic clinical history which informs healthcare profes-
sionals of the TTR in patients with NVAF attended in primary
care centers (PCCs) of the ICS. This project will evaluate the
impact of this tool on the adequacy of anticoagulant treatment,
the incidence of thromboembolic and hemorrhagic complica-
tions, and mortality at 2 years after the beginning of the
intervention. The evaluation of the impact of the intervention will
be performed based on the characteristics of the patients and the
healthcare professionals.2. Methods and design
2.1. Study design and setting
A cluster, randomized, clinical trial (type: parallel group) will be
performed with patients attended in the ICS primary care setting.
It is estimated that 5.8 million people are attended in ICS which
comprises 287 PCCs around Catalunya (source: Sistemes
d’Informació dels Serveis d’Atenció Primària (SISAP) of the
ICS, unpublished data).2.2. Participants
The study will be carried out in patients diagnosed with NVAF
receiving anticoagulant treatment.
2.2.1. Inclusion criteria (all criteria must be met). Patients diagnosed with NVAF 1 year prior to the implemen-
tation of the computerized tool;
Patients receiving anticoagulant treatment with DOACs or
VKAs;
Patients followed in primary care (with at least 6 INR controls
during the year prior to the intervention). The restriction
related to the INR controls is to minimize the variability in INR
at the initiation of treatment and avoid the effect that
temporary withdrawal of VKA anticoagulants might have
on the percentage of good INR control.
2.2.2. Exclusion criteria.

Patients with INR control in the reference hospital;
Patients with valvular AF (mitral stenosis); Patients with a prosthetic heart valve;
 Change to another PCC.2.3. Intervention
The clinical decision support tool for improving the adequacy of
AT in NVAF (CDS-NVAF) was developed by the ICS in
collaboration with primary care physicians in 2017. CDS-NVAF
Llorca et al. Medicine (2018) 97:3 www.md-journal.comis intended for patients diagnosed with NVAF and treated with
VKA. This tool calculates the TTR using the Rosendaal method
considering the last INR data. The INR data are found in the
clinical history of NVAF patients and are located on the screen of
the follow-up of oral anticoagulant use.
The CDS-NVAF will be activated when the physician
introduces the last INR value. At this time the TTR will be
calculated automatically. If the TTR value is <65%, a pop up
screen with an advisory text will open suggesting a change to
DOAC therapy. The physician can decide whether to change or
not the previous prescription. If the TTR value in >65% the pop
up screen will not appear. The TTR value will remain registered
on the screen of the follow-up of oral anticoagulant use and can
be consulted in future queries.
The diffusion of the CDS-NVAF will be made by an
announcement on the ﬁrst day of the intervention when the
healthcare professional opens the electronic clinical history.
The professionals of the intervention group will receive the
announcement and will be provided with the CDS-NVAF. The
professionals who are part of the control group will not receive
any of the above described information.
The implementation of the CDS-NVAF, and thus, the
beginning of the study is expected to December 15, 2017.
2.4. Sample size
In a ﬁrst approach the information system for primary care
research development (SIDIAP) established that during 2015
PCCs of the ICS had registered 171,472 cases of NVAF, 73,632
of whom were receiving anticoagulant treatment (63,001 VKAs
and 10,631 DOACs). Assuming a weight of 90%, an alpha error
of 5%, a control versus intervention ratio of 1, corrected for the
design by clusters and assuming a loss of 10%, our study will be
able to detect a difference of 1% for a rate of thromboembolic
events of 0.66%. Despite this power, a clinically relevant relative
reduction of 10% will be established.
2.5. Randomization
The randomization will be made by sectors of the ICS. A sector is
a group of PCCs that share 1 computer server. The ICS has 15
sectors. The sectors will be randomized using a simple
randomization method. From the generation of random numbers
(between 0 and 1) 2 groups will be created so that the numbers
with which the ﬁrst decimal is<5 will be rounded down to 0 and
the remaining will be rounded up to 1. The sectors associated
with 0 will constitute the control group and those associated with
1 will make up the intervention group. The study ﬂowchart is
presented in Figure 1.
2.6. Masking
The study will be blind for the trial participants, investigators of
the project and data managers, but will not be blind to the
physicians.
2.7. Data collection
The study variables will be collected from the SIDIAP population
database. The SIDIAP has anonymous data of 5.8 million
patients in the electronic medical registry system of the ICS and
complementary sources. This database includes the following
information: sociodemographic variables, healthcare activity,
and clinical variables. Pharmacy registries: Information on the
medications provided by pharmacies and the associated cost.3Laboratory tests. The anonymized data will be exported from the
SIDIAP to the statistical package used in the study.2.8. Outcomes
The outcomes of the study are as described below. Health events
will be classiﬁed according to the International Classiﬁcation of
Diseases-10 code. A schedule for data collection is presented in
Table 1.
2.8.1. Primary outcomes.(1) Incidence rate of thromboembolic events (acute myocardial
infarction or angina, ischemic stroke, peripheral embolism, or
transient ischemic attack [TIA]).
Incidence rates: Hemorrhagic events (intracranial hemor-(2)
rhage, gastrointestinal hemorrhage); All-cause mortality.
Adequacy of anticoagulant treatment: This variable encom-(3)
passes the adequacy of the anticoagulant treatment, taking
into account if an adequate change has occurred or not. The
adequacy of the AT in patients with NVAF will be based on
the fulﬁllment of the criteria of the ministry of health, social
services and equality of Spain, 2016[11] (Table 2).
0=No adequate change (when an inadequate change has been
produced or when an inadequate treatment has been maintained).
1=adequate change (when an adequate change has been
produced or when an adequate treatment has been maintained).
2.8.2. Secondary outcomes.(1) Sociodemographic characteristics of the patients: age, sex,
primary care area assigned, physician assigned;
PCC characteristics: teaching center, urban/rural, socioeco-(2)
nomic deprivation index (MEDEA), standard of healthcare
quality (SHCQ) and the standard of quality of pharmaceuti-
cal prescription (SQPP);
Characteristics of the professional: age, sex, PCC, type of(3)
work contract, SHCQ, SQPP;
Type of anticoagulant treatment: DOAC (dabigatran,(4)
apixaban or rivaroxaban), VKA (acenocoumarol orwarfarin),
heparin (with starting and completion date);
Type of treatment with risk of bleeding: antiaggregants,(5)
nonsteroidal anti-inﬂammatories, and selective serotonin
reuptake inhibitors (with starting and completion date);
Thromboembolic risk CHA2DS2-VASC (congestive heart(6)
failure, hypertension, age 75 years or older, diabetes mellitus,
previous stroke or TIA, vascular disease, age 65–74 years,
female) score (with date of determination). The score indicates
the risk of a patient with NVAF of suffering a stroke in 1 year.
The score goes from 0 (absence of risk) to 10 (greater risk);
Bleeding risk HAS-BLED (hypertension, abnormal liver/renal(7)
function, stroke, bleeding history or predisposition, labile
INR, elderly (>65 years), and drugs/alcohol) score (with date
of determination). The score allows the calculation of the risk
of bleeding in patients with NVAF receiving oral anticoagu-
lant treatment based on the risk factors associated with the
probability of bleeding. Score: 0= low risk; 1= intermediate
risk; 2= intermediate risk; ≥3=high risk;
Associated comorbidity (with date of diagnosis): diabetes(8)
mellitus, arterial hypertension, heart failure, chronic kidney
failure, nephropathy, abnormal liver function, alcoholism,
peripheral vasculardisease, stroke,peripheral embolism,orTIA;
Other determinations (with date of determination): creati-(9)
nine, systolic blood pressure, and ejection fraction.
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Figure 1. Study ﬂowchart. ICS=Catalan Institute of Health.
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To evaluate the initial functioning of the CDS-NVAF and to
promote technical improvements before the beginning of the
study, a pilot study was carried out for 15 days (from July 20,
2017 to August 3, 2017). The pilot study consisted in the
evaluation of 3 PCCs, 2 of which received the alert in the4electronic clinical history with the characteristics described in the
‘intervention’ section.
During the period of the pilot study, aspects about the
functionality of the CDS-NVAF and suggestions for improve-
ments were collected from the research team and the primary care
professionals (physicians, nurses, and referent professionals) in
work meetings. Some changes and suggestions for improvements
Table 1







Incidence rate of thromboembolic events ▪
Incidence rate of hemorrhagic events ▪
Incidence rate of mortality ▪





Primary care center characteristics ▪
Characteristics of the professional ▪
Treatment by anticoagulant treatment ▪ ▪
Treatments with risk of bleeding ▪ ▪
Thromboembolic risk CHA2DS2-VASC score ▪ ▪
Bleeding risk HAS-BLED score ▪ ▪
Comorbidities ▪ ▪
Other determinations ▪ ▪
HAS-BLED=hypertension, abnormal liver/renal function, stroke, bleeding history or predisposition,
labile INR, elderly, and drugs/alcohol.
Llorca et al. Medicine (2018) 97:3 www.md-journal.comon the part of professionals were incorporated to improve the
functionality of the CDS-NVAF.2.10. Statistical analysis
The statistical analysis will be performed at 3 time points: before
the implementation of the CDS-NVAF (baseline), at 1 year after
the beginning of the intervention (1-year follow-up), and at 2
years after the beginning of the intervention (2-year follow-up).
A descriptive analysis of all the variables studied will be carried
out using frequency and percentage for categorical variables and
mean, standard deviation, minimum, median, and maximum for
continuous variables. The Students’ t test (or the Mann–Whitney
U test in cases not fulﬁlling the criteria of normality) will be used
to determine possible differences in the means of the quantitative
variables between the 2 study groups. The Chi-square test (or
Fisher exact test) will be used for the qualitative variables. The
rates of incidence for each variable will be expressed as patient/
years with the corresponding conﬁdence intervals of 95%.
Analysis at a professional level: a logistic regression model will
be used to search for possible associations among the primary
outcome variables and the secondary variables. First, each
variable will be evaluated separately by univariate models and all
the variables that are statistically signiﬁcant or have a P .10 will
be included in the multivariate model.Table 2
Criteria on the adequacy of treatment with DOACs, according to
ministry of health, social services and equality from Spain (2016).
TTR of the INR values (INR=2–3) <65% during the previous 6 months (according
to the Rosendaal method) or, if calculation is impossible, the percentage of INR
within the therapeutic range (INR=2–3) <60% during the previous 6 months.
Presence of allergy or contraindications to VKA.
Patients with a history of intracranial bleeding.
Patients with ischemic stroke and clinical criteria of high risk of bleeding (HAS-BLED≥3).
Patients on VKA treatment with arterial thromboembolic episodes even with good INR
control.
DOAC=direct-acting oral anticoagulant; HAS-BLED=hypertension, abnormal liver/renal function,
stroke, bleeding history or predisposition, labile INR, elderly, and drugs/alcohol; INR= international
normalized ratio; TTR= time in therapeutic range; VKA= vitamin K antagonists.
5Analysis at a patient level: at this level hierarchal or multilevel
methods will be used to take into account the structure of the data
and to be able to introduce the variables of the patient in the
estimation of the effect of the intervention. The levels will be
professional (level 2) and patient (level 1). Multilevel logistic
regression models will be made to estimate the effect of the
intervention. The strategy of the analysis will be to estimate the
effect of the intervention considering professionals as the random
part. Afterwards, we will estimate the effect by introducing the
variables of quality of care of the professional level (SQPP and
SHCQ) and ﬁnally, we will study whether the introduction of
patient variables modiﬁes the effect of the intervention.
The level of signiﬁcance will be set at 5% and the statistical
package IBM SPSS Statistics v.23.0 for Windows will be used to
perform the statistical analyses.
2.11. Ethics and dissemination
The study will be carried out following national and international
norms (declaration of Helsinki) related to ethical aspects. This
study protocol (version 1, November 15, 2016) was approved by
the Ethical Committee of Clinical Investigation of the Institut
Universitari d’Investigació en Atenció Primària (IDIAP) Jordi
Gol, on March 15, 2017 (code P17/091). In addition, the study
has been authorized by the Direcció Assistencial d’Atenció
Primària of the ICS. The data included in the SIDIAP database
will be anonymized and will be identiﬁed by an internal code,
making subject identiﬁcation impossible even by the investigative
team, thereby guaranteeing the conﬁdentiality of the data of the
study participants included in the study according to the organic
law on the protection of personal data (15/1999 of 13 December,
LOPD). As the study is based on the analysis of an anonymized
database, informed consent will not be collected from the
patients. Any alteration of the study protocol will be submitted to
the ethical committee of the IDIAP Jordi Gol for approval and
will be published in clinical trials.gov.
The results of the study will be disseminated through
informative meetings addressed to professionals of the ICS,
communications to congresses, publications in scientiﬁc journals,
and in the clinical trials.gov webpage.
2.12. Safety
The CDS-NVAF may inﬂuence clinical decision-making and may
contribute in improving the adequacy of anticoagulant treatment
in patients treated with VKAs. Changes in treatments are
expected (from VKAs to DOACs), which would induce a
decrease in the incidence rates of thromboembolic and
hemorrhagic events in the medium and long term. Nonetheless,
the monitoring of possible adverse effects will be carried out by
the comparison of the incidence rates of the studied events
between the 2 groups (intervention and control), monthly during
the period of the intervention. If an increase in the incidence rates
in the intervention group is detected at anytime, the CDS-NVAF
will be deactivated by the principal investigator of the project. A
data monitoring committee will not be established, as the
evaluation of the adverse effects will be carried out by the SISAP
in coordination with the principal investigator of the project.3. Discussion
This is the ﬁrst study to provide family physicians in primary care
in Catalunya with a clinical decision support tool (CDS-NVAF)
to improve the adequacy of anticoagulant treatment in patients
[4] van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke
Llorca et al. Medicine (2018) 97:3 Medicinewith NVAF. The implementation of CDS-NVAF and its posterior
evaluation is currently considered to be a strategy of priority by
the ICS to improve the management of patients with NVAF and
subsequently reduce thromboembolic and hemorrhagic compli-
cations and death derived from poor control of VKA anti-
coagulation.
The present study may have a positive immediate impact on
clinical decision-making at the primary care level, with CDS-
NVAD inﬂuencing the daily clinical practice of the general
practitioners in ICS. On conﬁrming the good results expected, the
use of the CDS-NVAF can be extended to all ICS patients
diagnosed with NVAF in Catalunya.
The study has received ﬁnancial support to evaluate the results
of 2 years after the beginning of the intervention, however, taking
into account the importance of obtaining more knowledge on the
impact of healthcare results in the mid or long term, the
investigative team is seeking ﬁnancial support to assess the impact
of CDS-NVAF at 5 years postintervention.
The results obtained in the study may be of interest to all of
Spain as well as other countries with similar healthcare models
which use support tools for clinical decision-making.
With regard to the limitations of the study, the SIDIAP
database includes secondary data, and thus, there may be a
certain level of underregistration of variables of interest, although
this should not differ between the 2 study groups. The quality of
the registry is guaranteed in that most of the study variables make
up part of different indicators of quality (SHCQ and SQPP)
which are incentivated in the payment systems for objectives of
the ICS. There is no problem in the registry of the treatment
variables as the billing system of the pharmacy ofﬁces collects
these data. Another limitation is that the study is unblinded for
physicians and there may be contamination between groups
which may limit the conclusions of the study. Nonetheless, we
aim to evaluate the effectiveness of the intervention in the real-life
setting related to the usual clinical practice in which this type of
situation is frequent. The investigative team believes that
randomization by sectors and not by physicians will reduce
the probability of contamination between groups. Another
limitation of the study is that the tool provides information about
the adequacy of the VKA but not the adequacy of the DOACs,
which should be taken into account in result interpretation.
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